Cantor Fitzgerald Issues Pessimistic Forecast for Nyxoah (NASDAQ:NYXH) Stock Price

Nyxoah (NASDAQ:NYXH) had its target price reduced by analysts at Cantor Fitzgerald to $6.00 in a research note issued to investors on Monday,Benzinga reports. The brokerage currently has an “overweight” rating on the stock. Cantor Fitzgerald’s price objective would indicate a potential upside of 270.37% from the company’s previous close.

A number of other analysts also recently issued reports on NYXH. Weiss Ratings downgraded Nyxoah from a “sell (d-)” rating to a “sell (e+)” rating in a report on Friday, May 22nd. Robert W. Baird set a $2.31 target price on Nyxoah in a research report on Thursday, August 6th. Stifel Nicolaus decreased their target price on Nyxoah from $5.00 to $3.00 and set a “hold” rating for the company in a research note on Wednesday, June 17th. Piper Sandler reaffirmed an “overweight” rating and issued a $6.00 price target (down from $7.00) on shares of Nyxoah in a report on Thursday, August 6th. Finally, Wall Street Zen cut shares of Nyxoah from a “hold” rating to a “sell” rating in a report on Sunday, August 9th. Two analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $4.26.

Nyxoah Price Performance

Shares of NYXH opened at $1.62 on Monday. The firm has a market capitalization of $62.79 million, a price-to-earnings ratio of -0.64 and a beta of 1.62. The firm’s fifty day simple moving average is $1.55 and its 200-day simple moving average is $2.82. Nyxoah has a twelve month low of $1.26 and a twelve month high of $6.87. The company has a current ratio of 2.38, a quick ratio of 2.31 and a debt-to-equity ratio of 0.44.

Nyxoah (NASDAQ:NYXH) last issued its earnings results on Thursday, August 6th. The company reported ($0.67) EPS for the quarter, missing analysts’ consensus estimates of ($0.47) by ($0.20). The firm had revenue of $8.76 million for the quarter, compared to analyst estimates of $8.64 million. Nyxoah had a negative return on equity of 178.90% and a negative net margin of 443.16%. Equities analysts forecast that Nyxoah will post -1.5 EPS for the current fiscal year.

Institutional Investors Weigh In On Nyxoah

Several large investors have recently modified their holdings of the company. Heights Capital Management Inc. acquired a new position in shares of Nyxoah in the 4th quarter valued at $3,575,000. Shay Capital LLC acquired a new position in Nyxoah in the 2nd quarter valued at about $374,000. Deutsche Bank AG raised its stake in Nyxoah by 40.0% during the 4th quarter. Deutsche Bank AG now owns 35,000 shares of the company’s stock valued at $161,000 after acquiring an additional 10,000 shares during the last quarter. Citadel Advisors LLC purchased a new stake in shares of Nyxoah during the third quarter worth approximately $98,000. Finally, Bank of America Corp DE lifted its stake in shares of Nyxoah by 152.7% in the 3rd quarter. Bank of America Corp DE now owns 19,878 shares of the company’s stock worth $91,000 after acquiring an additional 12,012 shares during the period.

About Nyxoah

Nyxoah SA, headquartered in Mont-Saint-Guibert, Belgium, is a medical technology company focused on neuromodulation therapies for sleep‐disordered breathing. Established in 2018, the company’s primary offering is the Genio® system, a minimally invasive bilateral hypoglossal nerve stimulator designed to treat moderate to severe obstructive sleep apnea (OSA). By electrically stimulating the genioglossus muscle, the device helps maintain airway patency during sleep, reducing apnea events and improving overall sleep quality.

The Genio system comprises a small, implantable stimulator positioned submentally and an external activation unit worn by the patient.